Drug & Gene Information:
Relating to Drug: Irinotecan
Irinotecan is a cancer therapy drug.
UGT1A1 gene promoter usually have 5-8 TA repeat, most people with 6/6 TA repeat, few people are 6/7 or 7/7 TA repeat, 7 TA repeat genotypes were named for the UGT1A1*28.
- The more the number of TA repeat UGT1A1 protein expression is reduced, resulting in "Irinotecan" toxic side effects such as diarrhea or bone marrow suppression.
- 2006, the US FDA has genomic polymorphism of UGT1A1*28 polymorphism added Irinotecan drug labeling information, recommended suggest that screening for UGT1A1*28 polymorphism may identify patients with starting dose in patients.
- UGT1A1 Testing A laboratory test is available to determine the UGT1A1 status of patients. Testing can detect the UGT1A1 6/6, 6/7 and 7/7 genotypes.
- Pharmigene, Inc. conducted in development UGT1A1*28 gene test kit measure by HRM method ,and used sequence methods to validation.